A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
This proposed study is a randomized, double-blind, placebo-controlled, 3-arm parallel,
multicenter phase II study, designed to explore the efficacy and safety of SHR0302 treatment
for patients with moderate to severe atopic dermatitis.
The study will be conducted over a 12-week treatment period. Two active doses of SHR0302 will
be compared to placebo and improvement in atopic dermatitis will be assessed using the
Investigator's Global Score (IGA)